Category: Angiotech Pharmaceuticals Inc.
Private equity players Bain Capital, Carlyle Group and KKR & Co. are in the hunt for medical device company Carestream, said to be on the auction block for up to $3.5 billion.
At least 5 major private equity players are vying for medical device company Carestream Health, including Bain Capital, Carlyle Group and KKR & Co., according to Reuters.
Onex Corp. is hoping to unload Carestream, formed in the 2007 spinout of Eastman Kodak Co.'s healthcare business, for up to $3.5 billion, the news service reported.
Angiotech Pharmaceuticals sells its interventional products business back to previous overseer Argon Medical for $362.5 million, planning to use part of the funds to repay repay all of its outstanding debts.
Angiotech Pharmaceuticals plans to retire all of its outstanding debt obligations with part of the $362.5 million it stands to gain through the sale of its interventional products business back to Argon Medical Devices.
Angiotech Pharmaceuticals cuts losses in half during its 3rd quarter after the company undertook restructuring measures after filing for bankruptcy last year.
Angiotech Pharmaceuticals unveiled its 3rd quarter results, demonstrating narrowed losses in the year following the company's bankruptcy and restructuring efforts.
Angiotech and former president & CEO William Hunter reach an agreement in principle following a year-long severance package dispute.
Angiotech Pharmaceuticals reached an agreement in principal with former president & CEO William Hunter to settle a matter regarding Hunter's termination payments, with Hunter receiving more than double the company's initial cash offer.
Newt Gingrich's Center for Health Transformation files for Chapter 7 bankruptcy; also, device makers race to all-in-1 diabetes care; device tax is no big deal, say med-tech execs; Bioject's independent accountant resigns amid uncertainty; Gabelli puts some skin into Zoll; Hologic lands DoD contract worth up to $98 million; Angiotech sells Quill tech to J&J; MiMedx beats Q1 sales goals; EnteroMedics signs exclusive distribution with Bader Sultan & Bros.; Merck buys into VirtualScopics to the tune of up to $9 million; MTBC acquires GlobalNet; GE completes SeqWright acquisition; Elron subsidiaries near close on merger; American CryoStem and Protein Genomics join forces for wound healing; Hypertension Diagnostics gets building code violation; Abbott and Kensey Nash hit 52-week highs
The Center for Health Transformation, a health care think tank launched by GOP presidential hopeful Newt Gingrich, filed for Chapter 7 bankruptcy this week, listing liabilities of between $1 million and $10 million that it says it can't repay.
The organization's assets, which it listed in court filings at between $50,000 and $100,000, will be liquidated and the business may subsequently close.
Concerns about broken vena cava filters resurface as a Japanese study finds a high rate of fracture for Cordis Corp.'s TrapEase permanent implant.
TrapEase permanent vena cava filter
A new study reported a high fracture rate among permanent inferior vena cava filters made by Cordis Corp., a device-making arm of Johnson & Johnson (NYSE:JNJ).
In a Japanese study of 20 patients with Cordis' TrapEase IVC filter, the devices fractured in half the patients at 50 months.
